SKP2 and neoplasm: Wang Kai’s team has found in liver cancer that O-GlcNAc modification at the Ser34 site of SKP2 can enhance its binding ability to SKP1, stabilize the function of the SCF complex, promote the ubiquitination and degradation of p27 and p21, accelerate G1/S phase transition and drive tumor proliferation (54).